Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Amyotrophic Lateral Sclerosis Topic Center

News
Prototype Soft Robotic Wearable Restores Arm Function for ALS Patients, Hints at Future of Assistive Technology
03/16/2023
Brionna Mendoza
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable...
03/16/2023
Neurology
News
Ultrasound a Useful Tool for Detecting Dysphagia in ALS and Other Neurological Diseases
03/09/2023
Brionna Mendoza
Ultrasonography is an effective and convenient method for evaluating common swallowing disorders, like dysphagia, that are common in neurological diseases including amyotrophic lateral sclerosis (ALS).
Ultrasonography is an effective and convenient method for evaluating common swallowing disorders, like dysphagia, that are common in neurological diseases including amyotrophic lateral sclerosis (ALS).
Ultrasonography is an effective...
03/09/2023
Neurology
quiz
Quiz
How common is familial ALS?
02/21/2023
What percent of all ALS cases are familial (inherited or genetic)? Take this quick clinical quiz to find out!
What percent of all ALS cases are familial (inherited or genetic)? Take this quick clinical quiz to find out!
What percent of all ALS cases...
02/21/2023
Neurology
News
Trio of ALS Molecular Subtypes With Varying Patient Survival Identified
02/15/2023
Jolynn Tumolo
A patient stratification analysis identified 3 unique molecular subtypes of amyotrophic lateral sclerosis (ALS), which are associated with differences in patient prognosis.
A patient stratification analysis identified 3 unique molecular subtypes of amyotrophic lateral sclerosis (ALS), which are associated with differences in patient prognosis.
A patient stratification...
02/15/2023
Neurology
News
In ALS, MicroRNA Levels Closely Associated With Disease Occurrence
02/10/2023
Brionna Mendoza
MicroRNAs (miRNAs), specifically serums miR-206, miR-133b, and miR338-3p, have been identified as “potential promising biomarkers” for detecting amyotrophic lateral sclerosis (ALS), according to the results of a systematic review and...
MicroRNAs (miRNAs), specifically serums miR-206, miR-133b, and miR338-3p, have been identified as “potential promising biomarkers” for detecting amyotrophic lateral sclerosis (ALS), according to the results of a systematic review and...
MicroRNAs (miRNAs), specifically...
02/10/2023
Neurology
News
New Hallmark of Motor Degeneration in ALS Identified
02/02/2023
Brionna Mendoza
Loss of the RNA processing protein, SFPQ, in motor neurons has been identified as a probable molecular mechanism underlying the progression of amyotrophic lateral sclerosis (ALS) and a significant hallmark of the disease.
Loss of the RNA processing protein, SFPQ, in motor neurons has been identified as a probable molecular mechanism underlying the progression of amyotrophic lateral sclerosis (ALS) and a significant hallmark of the disease.
Loss of the RNA processing...
02/02/2023
Neurology
News
New ALS Drug Gets OK From FDA, Despite Lingering Efficacy Concerns
09/30/2022
Brionna Mendoza
On Thursday, the US Food and Drug Administration (FDA) approved sodium phenylbutyrate/taurursodiol (Relyvrio) to treat patients living with amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
On Thursday, the US Food and Drug Administration (FDA) approved sodium phenylbutyrate/taurursodiol (Relyvrio) to treat patients living with amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
On Thursday, the US Food and...
09/30/2022
Neurology
Doctor taking notes.
Quiz
Researchers recently advised that what be added to ALS assessments?
08/04/2022
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
08/04/2022
Neurology
News
FDA Rolls Out 5-Year Plan for Addressing Rare Neurodegenerative Diseases
07/06/2022
Jolynn Tumolo
The US Food and Drug Administration (FDA) recently announced its 5-year Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS).
The US Food and Drug Administration (FDA) recently announced its 5-year Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS).
The US Food and Drug...
07/06/2022
Neurology
News
ALS Treatment Trials May Require More Complex Statistical Models
06/28/2022
Jolynn Tumolo
The inability of placebo-to-active treatment crossover trials, involving patients with fatal conditions such as amyotrophic lateral sclerosis (ALS), to sustain a placebo group long enough to accurately assess survival may lead to an...
The inability of placebo-to-active treatment crossover trials, involving patients with fatal conditions such as amyotrophic lateral sclerosis (ALS), to sustain a placebo group long enough to accurately assess survival may lead to an...
The inability of...
06/28/2022
Neurology

Advertisement

Advertisement

News

A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Doctors examine brain scans
News
Rate of Frontotemporal Dementia in Patients With ALS Higher Than Previous Estimates
03/04/2024
Jolynn Tumolo
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Declines Accelerated Approval for Novel ALS Drug
01/05/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug Administration (FDA) declined to grant accelerated approval of the experimental drug CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).
The US Food and Drug...
01/05/2024
Neurology
Brain health
News
Environmental Pollutants Linked With Increased ALS Risk, Mortality
11/21/2023
Jolynn Tumolo
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was associated with amyotrophic lateral sclerosis (ALS) risk and mortality in a Michigan cohort.
An environmental risk score was...
11/21/2023
Neurology
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
News
Polygenic Score for ALS Reflects an Individual’s Cumulative Genetic Risk
07/18/2023
Jolynn Tumolo
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics. “This...
A novel scoring system may help...
07/18/2023
Neurology
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
News
Cerebrospinal Fluid Biomarker May Inform ALS Diagnosis, Treatment
06/14/2023
Jolynn Tumolo
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential biomarker may aid in the diagnosis and treatment of sporadic amyotrophic lateral sclerosis (ALS), according to a research letter published in the Journal of Neurology, Neurosurgery, and Psychiatry. 
A newly discovered potential...
06/14/2023
Neurology
A hand chooses a happy face with a neutral and unhappy face next to them
News
ALS Patients Evaluate Facial Expressions Differently, Even Without Cognitive Impairment
05/18/2023
Brionna Mendoza
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic lateral sclerosis (ALS) exhibit different gaze patterns when visually scanning human facial expressions compared to healthy controls, according to new study findings.
Patients with amyotrophic...
05/18/2023
Neurology
News
FDA Advisory Committee Backs Accelerated Approval of Tofersen for SOD1-ALS
04/24/2023
Jolynn Tumolo
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed 9-0 that a demonstrated reduction in plasma neurofilament light chain (NfL) concentration in patients with SOD1-ALS is reasonably likely to predict clinical benefit.
Members of the committee agreed...
04/24/2023
Neurology
News
ALS Therapy Receives FDA Orphan Drug Designation
03/21/2023
Jolynn Tumolo
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation to RAG-17, a novel short interfering RNA (siRNA) modality for the treatment of patients with amyotrophic lateral sclerosis (ALS), biopharmaceutical company...
The US Food and Drug...
03/21/2023
Neurology
News
Prototype Soft Robotic Wearable Restores Arm Function for ALS Patients, Hints at Future of Assistive Technology
03/16/2023
Brionna Mendoza
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable prototype that significantly assists upper arm and shoulder movement in people with amyotrophic lateral sclerosis (ALS) has been developed by a team of researchers from Harvard.
A soft robotic wearable...
03/16/2023
Neurology
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
News
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
08/08/2024
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive...
08/08/2024
Neurology
brain waves
News
High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke
08/08/2024
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose...
08/08/2024
Neurology
An illustration of a healthcare provider conducting a telehealth appointment
News
Teleneurology Visits Acceptable to Patients Across Neurologic Conditions
08/05/2024
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic...
08/05/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
DMD Gene Therapy Indication Expanded to Include Boys 4 and Older
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
News
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
07/23/2024
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug...
07/23/2024
Neurology
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
News
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
07/22/2024
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was...
07/22/2024
Neurology
a hand breaks a wooden human figurine in half
News
Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related...
07/18/2024
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement